{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:30:28Z","timestamp":1771659028579,"version":"3.50.1"},"reference-count":27,"publisher":"American Diabetes Association","issue":"1","license":[{"start":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T00:00:00Z","timestamp":1513728000000},"content-version":"vor","delay-in-days":42,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01-DK-081352"],"award-info":[{"award-number":["R01-DK-081352"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01-DK-099177"],"award-info":[{"award-number":["R01-DK-099177"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To determine whether biomarkers of inflammation and endothelial dysfunction are associated with the development of kidney dysfunction and the time frame of their association.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Biomarkers were measured at four time points during 28 years of treatment and follow-up in patients with type 1 diabetes in the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications (DCCT\/EDIC) cohort. In addition to traditional biomarkers of inflammation (C-reactive protein and fibrinogen), we measured interleukin-6 (IL-6) and soluble tumor necrosis factor receptors 1 and 2 (sTNFR-1\/2), markers of endothelial dysfunction (soluble intracellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin [sE-selectin]), and fibrinolysis (total and active plasminogen activator inhibitor-1 [PAI-1]). Renal outcomes were defined as progression to incident chronic kidney disease (stage 3 or more severe) or macroalbuminuria (albumin excretion rate \u2265300 mg\/24 h). Prospective multivariate event-time analyses were used to determine the association of each biomarker with each subsequent event within prespecified intervals (3-year and 10-year windows).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Multivariate event-time models indicated that several markers of inflammation (sTNFR-1\/2), endothelial dysfunction (sE-selectin), and clotting\/fibrinolysis (fibrinogen and PAI-1) are significantly associated with subsequent development of kidney dysfunction. Although some markers showed variations in the associations between the follow-up windows examined, the results indicate that biomarkers (sTNFR-1\/2, sE-selectin, PAI-1, and fibrinogen) are associated with progression to chronic kidney disease in both the 3-year and the 10-year windows.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Plasma markers of inflammation, endothelial dysfunction, and clotting\/fibrinolysis are associated with progression to kidney dysfunction in type 1 diabetes during both short-term and long-term follow-up.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc17-0867","type":"journal-article","created":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T01:20:10Z","timestamp":1510190410000},"page":"128-135","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":28,"title":["Association Between Inflammatory Markers and Progression to Kidney Dysfunction: Examining Different Assessment Windows in Patients With Type 1 Diabetes"],"prefix":"10.2337","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3313-1579","authenticated-orcid":false,"given":"Nathaniel L.","family":"Baker","sequence":"first","affiliation":[{"name":"Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8999-3587","authenticated-orcid":false,"given":"Kelly J.","family":"Hunt","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC"},{"name":"Ralph H. Johnson VA Medical Center, Charleston, SC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle R.","family":"Stevens","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabor","family":"Jarai","sequence":"additional","affiliation":[{"name":"Discovery Biology, Fibrotic Diseases, Bristol-Myers Squibb, Pennington, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn D.","family":"Rosen","sequence":"additional","affiliation":[{"name":"Translational Research and Discovery, Fibrotic Diseases, Bristol-Myers Squibb, Pennington, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard L.","family":"Klein","sequence":"additional","affiliation":[{"name":"Ralph H. Johnson VA Medical Center, Charleston, SC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Virella","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria F.","family":"Lopes-Virella","sequence":"additional","affiliation":[{"name":"Ralph H. Johnson VA Medical Center, Charleston, SC"},{"name":"Department of Medicine and Laboratory Services, Medical University of South Carolina, Charleston, SC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the DCCT\/EDIC Research Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2017,11,8]]},"reference":[{"key":"2022031301231334400_B1","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.2337\/dc08-0659","article-title":"Risk factors related to inflammation and endothelial dysfunction in the DCCT\/EDIC cohort and their relationship with nephropathy and macrovascular complications","volume":"31","author":"Lopes-Virella","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031301231334400_B2","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.2337\/diacare.26.7.2165","article-title":"Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study","volume":"26","author":"Schram","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031301231334400_B3","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s00125-004-1628-8","article-title":"Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes\u2014the EURODIAB Prospective Complications Study","volume":"48","author":"Schram","year":"2005","journal-title":"Diabetologia"},{"key":"2022031301231334400_B4","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.2337\/dc12-2521","article-title":"Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects","volume":"36","author":"Lopes-Virella","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031301231334400_B5","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2174\/0929867043364595","article-title":"Plasminogen activator inhibitor-1","volume":"11","author":"Gils","year":"2004","journal-title":"Curr Med Chem"},{"key":"2022031301231334400_B6","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N Engl J Med"},{"key":"2022031301231334400_B7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2337\/diacare.22.1.99","article-title":"Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort","volume":"22","author":"Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group","year":"1999","journal-title":"Diabetes Care"},{"key":"2022031301231334400_B8","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1093\/clinchem\/33.12.2267","article-title":"Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study","volume":"33","author":"The DCCT Research Group","year":"1987","journal-title":"Clin Chem"},{"key":"2022031301231334400_B9","doi-asserted-by":"crossref","first-page":"810","DOI":"10.2337\/diacare.26.3.810","article-title":"Serum lipoproteins in the diabetes control and complications trial\/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia","volume":"26","author":"Jenkins","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031301231334400_B10","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1046\/j.1523-1755.2003.00164.x","article-title":"Lipoproteins in the DCCT\/EDIC cohort: associations with diabetic nephropathy","volume":"64","author":"Jenkins","year":"2003","journal-title":"Kidney Int"},{"key":"2022031301231334400_B11","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.metabol.2004.05.004","article-title":"Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclasses","volume":"53","author":"Klein","year":"2004","journal-title":"Metabolism"},{"key":"2022031301231334400_B12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.atherosclerosis.2006.02.007","article-title":"Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes","volume":"190","author":"Lopes-Virella","year":"2007","journal-title":"Atherosclerosis"},{"key":"2022031301231334400_B13","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1464-5491.2006.01905.x","article-title":"Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT\/EDIC cohort: associations with carotid intima-media thickness","volume":"23","author":"Lyons","year":"2006","journal-title":"Diabet Med"},{"key":"2022031301231334400_B14","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2022031301231334400_B15"},{"key":"2022031301231334400_B16","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMoa1111732","article-title":"Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes","volume":"365","author":"de Boer","year":"2011","journal-title":"N Engl J Med"},{"key":"2022031301231334400_B17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.1994.03510280037029","article-title":"Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria","volume":"271","author":"Viberti","year":"1994","journal-title":"JAMA"},{"key":"2022031301231334400_B18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0002-9343(99)80226-5","article-title":"The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria","volume":"99","author":"Laffel","year":"1995","journal-title":"Am J Med"},{"key":"2022031301231334400_B19"},{"key":"2022031301231334400_B20","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jdiacomp.2005.06.005","article-title":"Soluble vascular cell adhesion molecule-1 and soluble E-selectin are associated with micro- and macrovascular complications in Type 1 diabetic patients","volume":"20","author":"Soedamah-Muthu","year":"2006","journal-title":"J Diabetes Complications"},{"key":"2022031301231334400_B21","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1464-5491.2005.01562.x","article-title":"Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in type 1 diabetic patients without clinically manifest macroangiopathy","volume":"22","author":"Targher","year":"2005","journal-title":"Diabet Med"},{"key":"2022031301231334400_B22","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.2337\/diacare.26.5.1439","article-title":"Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT\/EDIC cohort","volume":"26","author":"Klein","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031301231334400_B23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1399-5448.2006.00204.x","article-title":"Low risk of overt nephropathy after 24 yr of childhood-onset type 1 diabetes mellitus (T1DM) in Norway","volume":"7","author":"Skrivarhaug","year":"2006","journal-title":"Pediatr Diabetes"},{"key":"2022031301231334400_B24","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0049-3848(96)00021-7","article-title":"Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy","volume":"81","author":"Myrup","year":"1996","journal-title":"Thromb Res"},{"key":"2022031301231334400_B25","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1007\/s00125-003-1194-5","article-title":"Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients","volume":"46","author":"Saraheimo","year":"2003","journal-title":"Diabetologia"},{"key":"2022031301231334400_B26","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1681\/ASN.2011060628","article-title":"Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes","volume":"23","author":"Gohda","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2022031301231334400_B27","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1681\/ASN.2011060627","article-title":"Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes","volume":"23","author":"Niewczas","year":"2012","journal-title":"J Am Soc Nephrol"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc17-0867","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/41\/1\/128\/553486\/dc170867.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/41\/1\/128\/553486\/dc170867.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T05:11:55Z","timestamp":1647148315000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/41\/1\/128\/36627\/Association-Between-Inflammatory-Markers-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,8]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,11,8]]},"published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc17-0867","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,8]]}}}